Other Events · Jun 16, 2026Clearmind Medicine completes dosing for Part A of its FDA-regulated Phase I/II clinical trialCMNDClearmind Medicine Inc.On June 16, 2026, Clearmind Medicine announced the completion of dosing for Part A of its FDA-regulated Phase I/II clinical trial. The company is a pharmaceutical firm focused on developing medicines for neurological and psychiatric disorders.
